Skip to main content

Advertisement

SpringerLink
Log in

Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

The regulatory T (Treg) cells play a major role in the control of the autoimmunity and inflammation, and IL-35 has been described as an immunosuppressive cytokine that is mainly produced by CD4+ FOXP3+ Treg cells. The aim of this study was to evaluate the serum levels of IL-35 and a single nucleotide polymorphism (SNP), rs3761548, in FOXP3 gene in patients with multiple sclerosis. The blood samples were collected from 140 multiple sclerosis (MS) patients (including 51 untreated and 89 treated patients) and 140 healthy subjects as a control group. The serum levels of IL-35 were measured by ELISA. The DNA was analyzed for SNP rs3761548 in FOXP3 gene using SSP-PCR. There was no significant difference between untreated MS patients and control group regarding the mean serum levels of IL-35, although this parameter was higher in untreated patients. However, the mean serum level of IL-35 in treated MS patients was significantly higher than that in the control group (P < 0.008). The mean serum levels of IL-35 in patients who were treated with interferon-β, methylprednisolone, or with the both interferon-β and methylprednisolone were significantly higher than that in the healthy group (P < 0.01, P < 0.01, and P < 0.2, respectively). The frequencies of AA and AC genotypes at rs3761548 in the FOXP3 gene were significantly higher in MS group as compared with healthy subjects (P < 0.05). The frequency of CC genotype at rs3761548 was significantly lower in the MS group in comparison with healthy control subjects (P < 0.001). Moreover, the frequency of A allele was significantly higher whereas the frequency of C allele was significantly lower in MS patients in comparison to healthy subjects (P < 0.001). The mean serum level of IL-35 was significantly lower in MS patients or healthy subjects with AA genotype as compared with those with CC genotype at rs3761548 in FOXP3 gene (P < 0.01 and P < 0.001, respectively). These results showed higher serum levels of IL-35 in treated MS patients representing that the benefit effects of treatment may in part performed through the upregulation of the IL-35 production. The SNP rs3761548 may influence the susceptibility to MS disease and the serum levels of IL-35.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aranami T, Yamamura T (2008) Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 57:115–120

    Article  CAS  PubMed  Google Scholar 

  • Bai J, Qiu SL, Zhong XN, Huang QP, He ZY, Zhang JQ, Liu GN, Li MH, Deng JM (2012) Erythromycin enhances CD4+ Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediat Inflamm 2012:410232

    Article  Google Scholar 

  • Belladonna ML, Grohmann U (2013) Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnol Genet Eng Rev 29:149–174

    Article  CAS  PubMed  Google Scholar 

  • Belladonna ML, Grohmann U (2014) Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents. Biotechnol Genet Eng Rev 29:149–174

    Article  Google Scholar 

  • Buc M (2013a) Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediat Inflamm 2013:1–13

    Article  Google Scholar 

  • Buc M (2013b) Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediat Inflamm 2013:963748

    Article  Google Scholar 

  • Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG (2012) The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13:290–299

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Dasgupta A, Saxena R (2012) Regulatory T cells: a review. Natl Med J India 25:341–351

    PubMed  Google Scholar 

  • Gelati M, Corsini E, Dufour A, Massa G, Giombini S, Solero CL, Salmaggi A (2000) High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium. Can J Neurol Sci 27:241–244

    Article  CAS  PubMed  Google Scholar 

  • Graber J, McGraw C, Kimbrough D, Dhib-Jalbut S (2010) Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg 112:583–591

    Article  CAS  PubMed  Google Scholar 

  • Gravano DM, Vignali DA (2012) The battle against immunopathology: infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci 69:1997–2008

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • He Y, Na H, Li Y, Qiu Z, Li W (2013) FoxP3 rs3761548 polymorphism predicts autoimmune disease susceptibility: a meta-analysis. Hum Immunol 74:1665–1671

    Article  CAS  PubMed  Google Scholar 

  • Hirahara K, Poholek A, Vahedi G, Laurence A, Kanno Y, Milner JD, O’Shea JJ (2013) Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol 131:1276–1287

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Katoh H, Zheng P, Liu Y (2013) FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun 41:72–78

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Koziol JA, Wagner S, Sobel DF, Feng AC, Adams H-P (2005) Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. J Clin Neurosci 12:895–901

    Article  PubMed  Google Scholar 

  • Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248:156–169

    Article  PubMed  Google Scholar 

  • McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  • Miljkovic Z, Momcilovic M, Miljkovic D, Mostarica-Stojkovic M (2009) Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis. J Neuroinflammation 6:37

    Article  PubMed Central  PubMed  Google Scholar 

  • Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M (2010) Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol 218:120–124

    Article  CAS  PubMed  Google Scholar 

  • Oda JM, Hirata BK, Guembarovski RL, Watanabe MA (2013) Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases. J Genet 92:163–171

    Article  CAS  PubMed  Google Scholar 

  • Olson BM, Sullivan JA, Burlingham WJ (2013) Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 4:315

    Article  PubMed Central  PubMed  Google Scholar 

  • Peterson RA (2012) Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 40:186–204

    Article  CAS  PubMed  Google Scholar 

  • Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C (2008) Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin Neurol Neurosurg 110:992–996

    Article  PubMed  Google Scholar 

  • Seissler N, Schmitt E, Hug F, Sommerer C, Zeier M, Schaier M, Steinborn A (2012) Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients. Transpl Immunol 27:157–161

    Article  CAS  PubMed  Google Scholar 

  • Singer BD, King LS, D’Alessio FR (2014) Regulatory T cells as immunotherapy. Front Immunol 5:46

    Article  PubMed Central  PubMed  Google Scholar 

  • Szczucinski A, Kalinowska A, Losy J (2007) CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. Eur Neurol 58:228–232

    Article  CAS  PubMed  Google Scholar 

  • Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Sussmuth S, Lauda F, Kapfer T, Fang L, Senel M, Brettschneider J (2011) Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol 65:164–169

    Article  CAS  PubMed  Google Scholar 

  • Wang X, Ma C, Wu J, Zhu J (2013) Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models. J Neurosci Res 91:871–881

    Article  CAS  PubMed  Google Scholar 

  • Yamane H, Paul WE (2013) Early signaling events that underlie fate decisions of naive CD4+ T cells toward distinct T-helper cell subsets. Immunol Rev 252:12–23

    Article  PubMed Central  PubMed  Google Scholar 

  • Ye S, Wu J, Zhou L, Lv Z, Xie H, Zheng S (2013) Interleukin-35: the future of hyperimmune-related diseases? J Interferon Cytokine Res 33:285–291

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Research Center, Department of Neurology, Kerman University of Medical Sciences, Kerman, Iran

    A. Jafarzadeh & H. A. Ebrahimi

  2. Department of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran

    A. Jafarzadeh, M. Jamali, R. Mahdavi, H. Hajghani, A. Khosravimashizi, M. Nemati, M. M. Mohammadi & H. Daneshvar

  3. Department of Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    A. Jafarzadeh

  4. Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

    H. Najafipour

  5. Department of Immunology, Medical School, Dezful University of Medical Sciences, Dezful, Iran

    A. Sheikhi

Authors
  1. A. Jafarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Jamali
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mahdavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. A. Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Hajghani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Khosravimashizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Nemati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Najafipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Sheikhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. M. Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H. Daneshvar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Jafarzadeh.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jafarzadeh, A., Jamali, M., Mahdavi, R. et al. Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program. J Mol Neurosci 55, 891–897 (2015). https://doi.org/10.1007/s12031-014-0443-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-014-0443-z

Keywords

Search

Navigation